Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

NCT02381548 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

20

Enrollment

NIH

Sponsor class

Stopped Other - Adverse Events

Conditions

Acute Myeloid Leukemia
Acute Myeloid Leukemia Post Cytotoxic Therapy
Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive
Refractory Acute Myeloid Leukemia
Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive
Secondary Acute Myeloid Leukemia

Interventions

DRUG: Adavosertib
DRUG: Belinostat
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)